it was so great for regeneron. >> good for regeneron taking that on. >> ibm does a lot for awards, tooi've taken the winners out for dinner. we've been seeing techs doing better and better and better. meanwhile, dollar tree, dollar general, what's it say about our market today? what's it save? what is happening in this country? this is the middle class actually really suffering. all these politicians talk about it but when you go to the stores, i happen to like dollar tree very much because i am a candy guy. jim, go into cvs for candy, papa said it's a sin. does it really matter at this point that i have diabetes? he said i want you to buy them at dollar tree. >> dollar tree is up 9%. it diverges from what we've seen in retail. to your point, jim, yeah, there's huge disparity in income in this country and we're seeing that reflected perhaps on the frustration on the part of both left and right and very strong same-store sales from the likes of dollar tree and dollar general. >> the stuff is cheap. if you want to go have a holiday and get stuff to dress up your picnic, you go to one of

regeneron was up big. it reminded you these companies have pipelines.know that i didn't -- i said that they overpaid? i must have gotten half a dozen people who said they didn't overpay. to me pfizer they overpaid because the stock was the premium. but a lot of people said -- >> stock's trading above the big price right now. >> yeah. >> and i don't know, but we said this yesterday of course this seemed like a deal that might have been better for an allergan. perhaps some people speculating, nothing to offer there as to whether there's any shot of somebody trying to come up with a top for this name. but interesting it is trading a bit above -- >> anacor say the regeneron competitor is not nearly as efficient. this is terrible if you have something for humans, especially for pediatric, it's going to be a big seller. i don't know. people come up with -- they come up with very justifiable reasons why pfizer paid that price. >> right. and of course given the size it's not as though pfizer can't go other places and continue to add to what it wants to be a ver

sanofi has had a fabulous relationsh with regeneron in the past years. on how much they're able to buy, i find that the whole tenor of this is so different from the relationship with regeneron. they're pretty aggressive and always known as being consensual. what is going on here? >> they have, but a few years ago they were pretty aggressive. >> good point. >> they got it, i think they went up 12% or 13% from their original offer. so, you know, we'll see. they're not increasing the offer as of now, but the expectation is they'll certainly go to, you know, more than the 52-week high. >> it's putting a lot of bid on the biotech. a lot of people sensing the takeover market for biotech, i remember jnj saying we did not take the bait, we did not pay. i don't think they're going to speak about biotech. >> there's the president and prime minister abe. we're not going to take their statements in this bilateral, but when they get to q & a we'll try to take that live. >> let's head to rick santelli now check in at the bond pits at the cme group in chicago. rick. >>

regeneron has a new drug in the market for this as well. agree it's not synergistic but looks like pfizer has to do something. >> i know. but listen, maybe medivation some people have been speculating that's an oncology company, you could least make an understand why. by the way, cash they have plenty of it overseas, but the u.s. cash is precious. >> right. >> and to spend it on something like this -- >> and the premium is kind of absurd to me. do you think if they bought davita it would be anna cor cortcorta corta vida. >> do you write these down the night before -- >> if i would have had that one the night before i would have been able to do it. >> who's writing your material, jack bennie? >> no, i've got -- >> dennis miller sub referencing over here. >> i am using mory amsterdam -- >> dick van dike show. >> right. >> real quickly we can also hit tribune and gannett. we'll come back to some of this stuff later see how the stocks move. on gannett and tribune a big increase almost 100% premium at this point. there's not a path here. they ca

. >> regeneron shares up 5%. >> i really like this call. really like the trade setup. $360 a share has been support for this stock going back to february. three times that's where the buyers have come in. it's clear as a bell when you look at the chart. meantime, this is a company that could have 40%, 50% earnings growth next year launching new drugs. they are spending in support of that which crimps earnings near term but if you are an investor, this is probably a pretty good entry with a very well-defined point at which you would sell and say i'm wrong. >> okay. jc penney upgraded, outperform at baird. the stock's down almost 1.5% today. jim leventhal owns it in real life, now has added it back to the portfolio. he's got super conviction on this name. >> never heard of sears, huh? >> i don't know. >> everybody who attacked him last week which was kind of an attack, i don't remember who it was, josh and somebody else. >> yes. it was one. >> he isn't here. throw him under the bus. >> what do we think? >> i think, look, i have been wrong on

regeneron and celgene. >> i'm live here in new york city. getting ideas where to put money to work in this industry. and redeposition demonstrations for the first quarter in something. where are the opportunities out there? thanks for your time adam. this is -- can you share them here. >> i can't share the specific idea but i can talk about the broad -- the broad view. >> and that is what you -- >> -- macro. >> global macro fund. we just heard sam druckenmiller up there. i don't want to say ticking time bomb but there is a lot of concern. how would you describe the environment? >> well it's obviously complicated. we're seeing negative interest rates. which to us. we trade a lot of interest rates. so if you ask people 8 or 9 years ago whether you would have envisioned there would be negative interest rates. they would have said absolutely not. >> they look tot the john maynard cainess and everybody who spend no time on this concept because here we are presented with the reality and the theory doesn't fit. >> it's certainly a tax on cash. that